Literature DB >> 25139922

Transient cefuroxime/metronidazole treatment induced factor V antibodies.

Sjoerd Adrianus Antonius Van den Berg1, Patricia E Verwer2, René N Idema1, Coen Van Guldener2.   

Abstract

A 29-year-old patient presented with an appendicular infiltrate, initially treated with intravenous antibiotics, but later requiring percutaneous drainage. Both prothrombin time (PT) and activated partial thromboplastin time (aPTT) were prolonged on 3 days of antibiotic treatment and unresponsive to vitamin K or prothrombin complex concentrate. Laboratory investigation ultimately showed reduced factor V activity and factor V antibodies. In contrast to previously described cases of factor V antibodies, PT and aPTT were only mildly prolonged and residual factor V activity was still >20%. Draining of the abscess did not induce significant bleeding. Afterwards, no haemostatic medication was required. The patient was discharged from the hospital without complications. One week after cessation of the antibiotic treatment, PT and aPTT were within normal range again, with a factor V activity level of 36%. In conclusion, we present a patient with transient factor V antibodies, induced by antibiotics, without clinical bleeding tendency. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25139922      PMCID: PMC4139552          DOI: 10.1136/bcr-2014-205523

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  7 in total

Review 1.  Acquired factor V inhibitors: a systematic review.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  J Thromb Thrombolysis       Date:  2011-05       Impact factor: 2.300

2.  Lupus anticoagulants and their relationship with the inhibitors against coagulation factor VIII: considerations on the differentiation between the 2 circulating anticoagulants.

Authors:  Armando Tripodi; Maria Elisa Mancuso; Veena Chantarangkul; Marigrazia Clerici; Rossella Bader; Pier Luigi Meroni; Elena Santagostino; Pier Mannuccio Mannucci
Journal:  Clin Chem       Date:  2005-08-11       Impact factor: 8.327

3.  Deep-vein thrombosis and coumarin skin necrosis associated with a factor V inhibitor with lupus-like features.

Authors:  P W Kamphuisen; J Haan; P C Rosekrans; F J Van Der Meer
Journal:  Am J Hematol       Date:  1998-02       Impact factor: 10.047

Review 4.  Successful management of a possible antibiotic-related acquired factor V inhibitor: a case report and review of the literature.

Authors:  Pooja Motwani; Leslie Howard; Syed S Ali
Journal:  Acta Haematol       Date:  2012-12-19       Impact factor: 2.195

5.  Inhibitory anti-factor V antibodies bind to the factor V C2 domain and are associated with hemorrhagic manifestations.

Authors:  T L Ortel; K D Moore; M A Quinn-Allen; T Okamura; A J Sinclair; J Lazarchick; R Govindan; F Carmagnol; W H Kane
Journal:  Blood       Date:  1998-06-01       Impact factor: 22.113

6.  Factor V inhibitor in thrombosis.

Authors:  A Kapur; P R Kelsey; P E Isaacs
Journal:  Am J Hematol       Date:  1993-04       Impact factor: 10.047

Review 7.  Acquired factor V inhibitor. A problem-based systematic review.

Authors:  Ai Leen Ang; Ponnudurai Kuperan; Chin Hin Ng; Heng Joo Ng
Journal:  Thromb Haemost       Date:  2009-05       Impact factor: 5.249

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.